China Coronary Secondary Prevention Study (CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin J Cardiol 2005; 33 (2): 109–115.

Kou WR. Review on Bases and clinics of Xuezhikang Capsule. Chin J Intern Med 1998; 37(6): 364–367.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.

The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

China Coronary Secondary Prevention Study (CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin J Cardiol 2005; 33 (2): 109–115.

China Medical Tribune, 2005, http: //www.cmt.com.cn/ http: //www.medtrib.com.cn/ http: //www.cmt.org. cn/.

Lu ZL, Du BM, Wu YF, et al. Secondary prevention study of coronary heart disease in aged patients using Xuezhikang. Chin J Geriatr 2005; 24 (11): 805–808.

Kou WR. Review on basic and clinical research of Xuezhikang. Chin J Intern Med 1998; 37(6): 364–366.

Kou WR. Survey on basic and clinical research of Xuezhikang. China Prescript Drug 2005; 7: 62–67.

Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-in-flammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004; 24: 915–920.

Zhao SP, Liu L, Cheng YC, etal. Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis 168(2003): 375–380.

China coronary secondary prevention study(CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin JCardiol 2005; 33(2): 109–115.

Lu ZL, Du BM, Wu YF, et al. Secondary prevention study of coronary heart disease in aged patients using Xuezhikang. Chin J Geriatr 2005; 24(11): 805–808.

Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time coure study in patients with stable angina. Clin Chim Acta 2005; 352(1-2): 217–224.

Yang HB, Tang YS, Xu FY. Effect of Xuezhikang on vascular endothelial function and blood level of nitric oxide and endothelin in patients with hyperlipidemia. Chin J Integr Tradit West Med 2003; 23(1): 13–15.

Liu ZG, Yu XY. Effect of Xuezhikang Capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia. Chin J Integr Med 2004; 10(4): 259–262.

Wu JY, Shao HP, Liu YM. Xuezhikang reduces serum soluble adhesion molecules in hyperlipidemics. J Lanzhou Med Coll 2000; 26(1): 10–12.

Huang J, Liu CH, Zhang LJ. Effects of Xuezhikang on plasma levels of sICAM-1 and PAI-1 in patients with essential hypertension. J Postgrad Med 2004; 27(1): 19–25.

Lu XX, Liang GF. Effects of oxidized low density lipoprotein and Xuezhikang on nitric oxide synthase activity and intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. J Clin Cardiol 2004; 20 (6): 355–357.

Yao QH, Cui CZ, Wang JK, et al. Effect of Xuezhikang on blood lipids, serum oxidized low density lipoprotein, C-reactive protein and fibrinogen in patients with unstable angina pectoris. Chin J Integr Tradit West Med 2003; 23 (10): 750–752.

Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004; 110: 915–920.

Wang M, Shen JJ, Huang SE, et al. To compare the effects of different dose Xuezhikang with provastatin on blood lipids and inflammatory factors in patients with acute coronary syndrome. Prev Treat Cardio Cereb Vasc Dis 2005; 5(5): 14–16.

Tian JW, Fang Y, Wu LR, et al. The short-term effect of Xuezhikang and atorvastatin on inflammatory factors in patients with acute coronary syndrome. Chin J Pract Chin Modern Med 2004; 4(17): 1745–1747.

Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta 2005; 352(1–2): 217–224.

Liu L, Zhao SP, Cheng YC, et al. Xuezhikang decreases serum lipoprotein (a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003; 49(8): 1347–1352.

Shi XY, Zhu ZM, Liu YM, et al. Changes of Lipoprotein (a) in patients with atherosclerosis and effects of Xuezhikang treatment on them. Tianjin Med J 2001; 29 (7): 402–404.

Qiu YA, Huang SL, Chen YQ, et al. Proapoptotic effect of angiotensin II on cultured endothelial cells and protective effect of Xuezhikang. Acta Acad Med Jiangxi 2005; 45(2): 11–17.

Zhang PH, Li P, Hang XN. Inhibitory effect of Xuezhikang on matrix metalloproteinase 2 secreted by macrophage. Chin J Cardiol 2001; 29(8): 497–499.